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Background: The putative role of the gut in amplification of systemic inflammation in acute pancreatitis is gaining credence,
and intraluminal nutrition has been shown to decrease inflammation in experimental models of pancreatitis. Prepyloric feeding
often is used in people with acute pancreatitis, but has not been evaluated in dogs.
Hypothesis: Early intervention with enteral nutrition (EN) delivered proximal to the pylorus will be well tolerated in dogs
with acute pancreatitis and provide justification for further larger trials.
Animals: Ten dogs with severe acute pancreatitis in an open-label, prospective pilot study.
Methods: Dogs were treated with plasma transfusion and standard care, and then consecutively assigned to receive either
EN via esophagostomy tube feeding or parenteral nutrition (PN). Outcome was used to determine optimal study size for future
studies, and complications were compared between the 2 groups.
Results: A significantly greater number of vomiting or regurgitating episodes occurred in dogs receiving PN. The dogs
receiving EN did not demonstrate any noticeable postprandial pain. There were more catheter-related complications in the PN
group. There was no difference in outcome between the 2 treatments, and 43 dogs for each treatment would be required in
future studies to determine a difference in outcome.
Conclusions and Clinical Relevance: Early EN delivered proximal to the pylorus is well tolerated in dogs with severe pan-
creatitis and resulted in fewer complications than PN. Prospective trials in a larger cohort are justified to fully establish the
potential benefit of early EN, preferably compared with minimal enteral nutrition.
Key words: Nutrition-small animal; Pancreatic necrosis; Total parenteral nutrition.
A
cute pancreatitis has a high mortality rate in dogs,
and surviving animals often require intensive treat-
ment and hospitalization.1–3 Apart from general
recommendations regarding correction of fluid, electro-
lyte, and acid-base abnormalities, there remains a
paucity of information regarding specific management
of acute pancreatitis in dogs.
Nutritional management of acute pancreatitis is diffi-
cult because of the presence of substantial catabolism,
pancreatic necrosis, increased metabolic demands, and
complications of ileus.4 Historically, the nutritional rec-
ommendation for management of acute pancreatitis has
been ‘‘strict pancreatic rest,’’ in the belief that fasting
results in no feedback that will further stimulate exocrine
pancreatic secretion, thus protecting against autodiges-
tion to some extent.2 However, this theory has been
questioned, because it has been extrapolated from stud-
ies of healthy people and has not been proven in dogs. In
fact, 3 experimental studies have suggested that there is
minimal to no negative pancreatic feedback in dogs given
nutrition in both the jejunum and duodenum.5–7 It also
has been demonstrated in experimental models in ro-
dents and in people with naturally occurring disease that
exocrine pancreatic secretion is in fact decreased during
pancreatitis, and the decrease is most prominent in severe
inflammation.8,9
In people and in studies using animal experimental
models, fasting leads to intestinal mucosal atrophy, in-
creased rate of enterocyte apoptosis, decreased glutamine
and arginine transport, changes in mucin composition
of goblet and deep crypt cells, and a breakdown in the
intestinal barrier resulting in increased intestinal per-
meability.10–14Additionally, the gut itself may either start
or contribute to the systemic inflammatory response in
acute pancreatitis.15 Intraluminal nutrition is the most
potent stimulator of intestinal mucosal regeneration be-
cause of stimulation of growth factors and mucosal
blood flow. In addition, enteral nutrition (EN) may de-
crease sphlanchnic cytokine production, modulate the
acute phase response, decrease catabolism, and preserve
protein.16
Experimental models of pancreatitis in dogs have
shown a benefit of early intraluminal nutrition compared
with parenteral nutrition (PN) in decreasing bacterial
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translocation and down-regulating the severity of inflam-
mation.17–19 There also have been several clinical trials in
people demonstrating benefit in early EN compared with
PN for treatment of acute pancreatitis, with fewer infec-
tious complications, and in severe cases improved
outcome and decreased length of hospitalization.20–27
However, meta-analysis of these studies does not show a
clear benefit of early EN compared with PN, and there
are no well-constructed randomized-controlled trials
comparing EN to nothing PO.20,26 More recent studies
in people also suggest that gastric feeding (rather than
jejunal) is well tolerated and safe, with no exacerbation of
pain.24,25,27
A previous paper determined that there was no statis-
tical difference in the indirectly measurable pancreatic
response to diets of variable fat content in healthy dogs.28
This, along with the changing paradigm of feeding in
people with severe acute pancreatitis, formed the back-
ground to this pilot study evaluating the tolerability of




Ten dogs with a diagnosis of acute pancreatitis were recruited
into the study within 12–24 hours of admission to Murdoch Uni-
versity Veterinary Hospital. The study was approved by the
Murdoch University Animal Ethics Committee. Informed, signed
owner consent was obtained.
The diagnosis of acute pancreatitis was based on a combination
of clinical signs (abdominal pain, vomiting), serum canine pancre-
atic lipase 4200mg/L and, in all dogs, the presence of appropriate
pancreatic changes on abdominal ultrasonography performed by a
board-certified radiologist with a curvilinear 8MHz or linear
15MHz probe.a These ultrasonographic changes included diffuse
enlargement of the pancreas, hyperechoic mesentery surrounding
the pancreas, and variable pancreatic hypoechogenicity as pub-
lished previously.1,29,30 Dogs were excluded if other disease that
could cause secondary pancreatic inflammation, such as septic peri-
tonitis or pancreatic neoplasia, were evident during or after
completion of the study, with a follow-up period of 2–4 years. Dogs
had to weigh 410 kg to comply with the volume of blood sampling
required, and not have concurrent diabetic ketoacidosis. Only dogs
that showed substantial consequences of their disease (eg, dehydra-
tion, pain, hypovolemia, persistent vomiting, other systemic effects)
necessitating hospitalization and IV fluid therapy were recruited.
Initial Patient Assessment and Treatment
Historical and clinical information including signalment, poten-
tial inciting factors, previous medical history, physical examination
findings, days of clinical illness preceding admission, days fasting,
and the clinical severity score as published previously were recorded
for each dog on admission (Day 0).31 After recruitment into the
study, all dogs had baseline hematology, biochemistry (including
glucose, cholesterol, lipase, and amylase), electrolytes, and urinaly-
sis performed.
All dogs received IV fluid therapy (with crystalloids with ap-
propriate electrolyte supplementation) calculated to correct
dehydration and ongoing losses on an individual basis. Antiemetic
medication (metoclopramide,b 1–2mg/kg/d constant rate infusion)
and analgesia (including fentanyl continuous rate infusion and
patches, methadone, tramadol, lignocaine continuous rate infusion,
and morphine via epidural) also could be administered based on in-
dividual requirements. These treatments were initiated before
inclusion into the study for all dogs. Within the first 12 hours of
admission to the study, a nasoesophageal feeding tube was inserted
and a low-rate (0.5mL/kg/h) infusion of a balanced electrolyte
solutionc was started in all dogs. Fresh frozen plasma (10mL/kg/d)
was administered to each dog for the first 2 days of the study.
Antibiotics (ampicillind 25mg/kg IV q8h and metronidazolee
10mg/kg IV q12h) were to be given if dogs had a neutrophil
count o2.0  109/L or a left shift in combination with pyrexia
(rectal temperature 4391C), unless another specific indication was
present. Additional antiemetic (prochlorperazinef) therapy could be
administered if clinically indicated.
Treatment Groups
Dogs were consecutively assigned to 1 of 2 treatment groups, PN
or EN via esophageal tube feeding within the first 12–24 hours of ad-
mission, as described below. The first 24 hours of the study protocol
was designated Day 1, with continuation in the study until the end of
Day 3. After that time, treatment decisions including nutritional in-
tervention were based entirely on individual dog requirements and
not on the basis of the treatment assignment during the study.
All dogs were anesthetized with IV alfaxang (1–2mg/kg) and inhala-
tional isofluraneh with full anesthetic monitoring. A brief
endoscopic examination of the esophagus was performed to subjec-
tively assess the presence of moderate to severe esophagitis, to
account for esophagitis as a confounding factor for causing regur-
gitation or lack of tolerability for EN in individual dogs. This was
done both at the time of the endoscopy and retrospectively with
blinded review of the recordings by two of the authors (C.S.M.,
F.E.J.).
The dogs receiving PN had double-lumen jugular 16G catheters
inserted under sterile conditions and the dogs then were recovered
from anesthesia. PN administration was started within 2 hours of
anesthetic recovery, at a rate of 50% resting energy requirements
(RER) on Day 1 and 100% on Day 2. For every 100 kcal of calcu-
lated RER, an additional 4 g of protein (14 kcal) was added. This
meant that 17.5% of the calories were supplied as lipid and 70.2%
as 50% dextrose, along with 12.3% amino acid solution. Full asep-
sis was used when checking the jugular catheter site daily.
The dogs receiving EN had large gauge (14–16Fr) single lumen
feeding tubes inserted in the esophagus and secured externally be-
fore recovery from anesthesia. Dogs were fed within 2 hours of
recovery. A total of 1/3 of their daily calculated calories (RER 
1.25) was fed, divided every 6 hours on Day 1, 2/3 on Day 2, and
100% on Day 3. They were fed a low-fat commercial dog foodi with
a fat content of 1.7% (1.9 g) per 1,000 kcal. This diet was supple-
mented with commercial enteric-coated pancreatic enzymesj at
5,000U/feed if body weight o15 kg, 10,000U/feed body weight
15–30 kg, or 25,000U/feed if body weight 430 kg. Medium chain
triglyceride oilk (C8 and C10 fatty acids composition 495%) also
was supplemented at 1.0mL/kg/d in divided doses, as established in
a previous study to minimize pancreatic response.28
Monitoring
Full daily clinical records were kept for each dog, including re-
sults of physical examination, clinical severity score as published
previously, presence of any complications, vomiting, or regurgita-
tion events (these were not differentiated as they were not always
observed), baseline clinicopathologic data, and body weight.31
Daily pain score by 1 of 2 authors (C.S.M. or F.E.J.) was recorded
from admission until Day 3, and used to modulate analgesic ther-
apy. The pain score ranged from 0 to 10, adapted from previously
published criteria, with a score of 2 indicating mild discomfort,
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7 moderate to severe pain, and 10 severe pain causing substantial
alterations in mentation.32
Blood was collected into plain and EDTA containers daily via
cephalic or jugular venipuncture before the start of nutritional sup-
port at admission into the study (Day 1) until completion of study
(Day 3) in all dogs and on Day 1, 5–10 minutes after the 1st feed in
the EN dogs. Blood was collected into chilled tubes, stored on ice to
allow clotting and then centrifuged at 101C at 5,000 rpm for 5 min-
utes before harvesting sera or plasma and storing at 181C.
Serum samples were shipped on dry ice for measurement of
canine trypsin-like immunoreactivityl (cTLI), canine pancreatic-
specific lipasem (s-CPL), and C-reactive proteinn (CRP), which all
were measured at the same laboratory by enzyme-based assays that
have been validated previously in dogs.33,34 Reference intervals for
these markers in dogs are 5.7–45.2, 0–200mg/L, and 0–7.6mg/L,
respectively. Frozen plasma and serum samples were transported
for measurement of gastrino at a local laboratory. A previous study
had established a reference range for gastrin in healthy dogs of
o5–16 pg/mL and results o4.77 pg/mL were recorded as 4.77.28
Additional aliquots of serum were shipped on dry ice for measure-
ment of serum pancreatic elastase-1 (PE-1).p Gastrin, cTLI, and
s-CPL were measured at all time points in all dogs. CRP and
elastase were measured at all time points, except the postfeed sam-
ple in dogs from the EN group.
Statistical Analyses
Differences in clinical severity scores, esophagitis, duration of
clinical signs preceding hospitalization, and blood marker concen-
trations (cTLI, s-CPL, gastrin, CRP, and PE-1) between the 2
treatment groups at admission were assessed by 1-way ANOVA
analysis. The number of vomiting or regurgitation episodes and the
number of days each animal was hospitalized both were analyzed by
a Poisson model for an effect of treatment. Significance of the esti-
mated b-coefficient was determined at P o .05. The b estimate was
exponentiated to determine the ratio of the incidence of events. The
proportion of dogs surviving after each treatment was compared by
Fisher’s exact test with significance determined at P o .05 by a
2-sided probability. In the face of a nonsignificant result, the sample
size required to prove this difference with 95% confidence interval
at a statistical power of 80% was determined. PROC GENMOD
and PROC FREQ were used for all analysis.q
Results
There were 4 neutered females and 6 neutered males in
the study. The median age was 7 years, with a range of 2–
11. The median body weight was 26.1 kg, with a range of
14.8–48.6 kg. There were 3 cross breeds and 1 each of Si-
berian Husky, Beagle, Bull Terrier, Weimeraner, Golden
Retriever, Border Collie, and Rhodesian Ridgeback. All
dogs that survived this episode (n 5 9) were still alive at
2-year follow-up, some up to 4 years. No dog received
PN after the initial 3-day period. One dog had hyper-
lipidemia on admission that persisted after recovery, and
required ongoing management, and may have contrib-
uted to the development of acute pancreatitis. This dog
received EN. No underlying cause was definitively iden-
tified in the other 9 dogs, but dietary indiscretion was
suspected in 2. No abnormalities in serum glucose con-
centration were present in any dog at any time point. All
dogs had serum canine pancreatic lipase 4300mg/L,
with 8 having concentration 4800mg/L. The median,
mean, and range for clinical severity score, duration of
signs before admission into the study, serum C-RP
concentrations, and concentrations for gastrin, cTLI,
PE-1, and s-CPL are presented in Table 1. There was no
significant difference between treatment groups for any
of these variables.
All dogs in the EN group survived, whereas 1 dog in
the PN group died. The proportion surviving was not
different between treatments (P 5 1.0). Using this result
of a binomial proportion of survival of 5/5 versus 4/5, the
calculated sample size to conclude a difference with 95%
confidence interval (at 80% power) would be 43 in each
group. If the number of controls (PN) versus treated
(EN) was 2 : 1, the sample size required decreases to 35,
with 70 controls.
Adverse reactions or complications occurred in 3 dogs
in the EN group, but were considered mild or short term.
These included abdominal pain refractory to increasing
analgesic modalities for the first 36 hours of the study
(1 dog), urinary tract infection (1 dog), pyoderma
(1 dog), and esophagostomy tube site infection (the same
3 dogs). The tube site infections were considered mild ex-
cept in the 1 dog that had preexisting severe pyoderma.
Discontinuation of tube feeding was not required in any
dog. The 3 dogs in this group with documented infection
all received cephalexin.r The dog with refractory pain
(pain scores were Day 0: 8, Day 1: 4, Day 2: 1) did not
demonstrate any exacerbation of the pain after tube feed-
ing, and the pain decreased substantially by Day 2.
Analgesics used in this dog initially were buprenorphine,
then methadone along with fentanyl continuous rate
infusion, and then combined fentanyl and lignocaine
continuous rate infusion. Analgesia was not necessary
after Day 3. In the PN group, jugular phlebitis occurred
in 4 dogs, with 1 severe enough to cause caval syndrome
and require removal of the catheter on Day 3. One dog
had refractory abdominal pain and a pancreatic pseudo-
cyst that developed after the treatment trial had been
completed (Day 4) and required percutaneous ultra-
sound-guided drainage. The dog in this group that died
developed extrahepatic bile duct obstruction and pleural
effusion. One dog had no complications.
In the EN group, only 1 dog had 3 episodes of vomit-
ing or regurgitation over 7 days of hospitalization,
whereas in the PN group 3 dogs had 33 episodes (1 had
22 in 6 days of hospitalization, 1 had 9 in 10 days, and
1 had 2 in 5 days). There was a significant effect of treat-
ment on the number of vomiting or regurgitation
episodes (P o .001), with the ratio of the incidence of
episodes for parenteral versus EN estimated at 11.0 (95%
confidence interval 3.4–35.8).
Discussion
This pilot study supports the notion that early EN
delivered proximal to the jejunum is well tolerated in
dogs with severe pancreatitis. It may also be considered
that PN could be detrimental in dogs with acute pancr-
eatitis because of the high number of complications, but
this may be an institutional bias as there were fewer com-
plications in the EN group than the PN group. The
complications and adverse effects seen with PN were all
related to catheter sepsis, and none with the composition
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of the infusion. None of the PN group had hyper-
glycemia, hyperlipidemia, refeeding syndrome, or
hypervolemia at any point, all of which have been asso-
ciated with a poor outcome in critical care settings in
both people and animals.4,35,36 The 1 dog that had pre-
existing hyperlipidemia was in the EN group. Because of
this, it would seem logical to assume that any benefits
seen with EN are because of direct nutritional delivery to
the intestinal lumen rather than total caloric input alone.
The additional RER administered to the PN group
(14%) and the EN group (25% by Day 3) is unlikely to
have had detrimental effects, because RER is only an
estimate of daily calorie requirements that may vary
from measured direct calorimetric energy requirements
as much as 25% in individual patients.37
One major argument against prepyloric (or gastric)
feeding in pancreatitis is that it will be poorly tolerated
because of decreased intestinal motility. Certainly in our
population of dogs this was not the case. There were sig-
nificantly more vomiting or regurgitation episodes in the
PN group than in the EN group. This could be attribut-
able to differences in patient selection; however, case
allocation was consecutive, there was no difference iden-
tified between groups at onset of the study, and no
animal was selected for the study on the basis of the pro-
spective treatment group. Additionally, all animals had
decreased gut sounds on admission. ENmay improve gut
health to a point that minimizes ileus and vomiting, al-
though this could not be conclusively determined from
this study. Although prokinetic agents such as cisapride
were allowed by the study protocol, they were not needed
in any animal. Initially, all animals had metoclopramide
constant rate infusion as part of their treatment, and
there may have been a prokinetic benefit conferred from
this treatment. This prokinetic treatment was given to all
dogs, and consequently is unlikely to have influenced the
frequency of vomiting or regurgitation between groups.
There were similar degrees of esophagitis visible grossly
in both groups, but no statistical comparison was made
because of the poor sensitivity of detecting esophageal
inflammation on visual assessment.
Another argument against feeding proximal to the
jejunum is the possible development of pancreatic pain.
There was no temporally associated abdominal pain ob-
served when feeding was commenced in any of the EN
dogs. One dog in the EN group had substantial pain on
admission that was initially refractory to increasing an-
algesia, but this declined rapidly after Day 2 while still
receiving EN, and did not appear directly associated with
feeding. All analgesia could be discontinued in this dog
by Day 4. Also, the dog that developed an acute pancre-
atic fluid collection (previously called a pseudocyst) was
in the PN group. One possible hypothesis for acute fluid
collection is increased and persistent pancreatic enzyme
leakage, and so if stimulation of the pancreas in acute
pancreatitis is increased with intraluminal nutrition, de-
velopment of acute fluid collections could be expected to
be more likely in a dog given EN.
Another argument against prepyloric feeding is that it
will increase pancreatic secretion by food stimulus within
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showed any adverse effects from feeding. The need to
avoid stimulus of the duodenum in acute pancreatitis
does not appear to be upheld by this study.
Currently, the recommendations of many gastroentero-
logy societies in human medicine is to supply EN early in
severe (but not mild) pancreatitis because there is a re-
duction in mortality and infectious complications.38–42
There is still extensive debate about the advisability of these
recommendations.
In this study, we primarily wanted to evaluate 2 methods
of interventional nutrition, and all dogs received a
high level of baseline care. This care included plasma trans-
fusion and trickle esophageal electrolyte administration, so
that any difference between the 2 groups could be attrib-
uted to the interventional nutrition alone. It is questionable
whether plasma transfusion actually confers a positive ben-
efit, as was recently proposed in 1 retrospective study of
dogs with pancreatitis.43 However, a prospective compari-
son between animals with similar degrees of disease
severity is needed before a definitive determination can be
made about whether or not plasma administration pro-
vides any benefit in dogs with pancreatitis.
A limitation of the current study was the fact that
study observers were not blinded to the treatment
groups, leading to the possibility that bias may have in-
fluenced results. Given that the 2 treatment modalities
were so different, it proved difficult to adequately blind
the clinicians involved. To overcome this in the future, it
is suggested that treatment groups be randomly assigned
and not known to the observer until the patient has been
recruited into the study. This will remove the bias of se-
quential treatment group assignment, as a clinician may
not actively recruit a dog into the study if he or she feels
the treatment is not suitable for that animal.
Relying on ultrasound examination for diagnosis may
have meant that some dogs with pancreatitis that were
presented to the center were not recruited for this study.
However, this study was aimed at assessing efficacy of
treatment in severely affected dogs, and false-positive
diagnoses were unlikely in this group. All of the surviving
9 dogs were still alive 2–4 years later, and the nonsurviv-
ing dog had a full postmortem examination that did not
identify any changes unrelated to severe pancreatitis, and
diseases such as pancreatic neoplasia or septic peritonitis
seemed extremely unlikely.
The diet chosen in this study was based on a previous
study that assessed which dietary combination led to
minimal pancreatic stimulation in healthy dogs.28 Extra-
polation of this diet to dogs with pancreatic disease is
not supported, nor indeed is it known if dietary modifi-
cation is even necessary if there is minimal pancreatic
stimulation during acute pancreatitis. As there were no
adverse effects associated with feeding, it can only be
concluded that the diet used was not detrimental. There
may be additional or unknown benefits from adding
supplements such as fiber, probiotics, o-3 fatty acids,
or glutamine, as has been suggested in some studies in
people.44–47
Certainly, the optimal treatment of pancreatitis can-
not rely on a single modality, nor does this pilot study
suggest that early EN necessarily is beneficial in severe
pancreatitis. Rather, this study is an initial step in trying
to establish the best nutritional options for dogs with
pancreatitis. It would seem logical from the data from
humans and dogs to restrict the use of interventional EN
to dogs with severe disease, but the optimal timing and
type of nutrition is yet to be established. It was calculated
that 35–43 dogs would need to be treated with EN in a
prospective study to determine whether there is a statis-
tical difference in survival or days between PN and early
EN. Future studies also should assess the number of days
intensive management is required or the number of days
until voluntary food intake occurs between the 2 groups.
The authors feel that because of the high number of
technical complications and adverse catheter effects that
PN should be reserved for those dogs that cannot
support any form of EN after a period of 4–5 days of
anorexia. Because esophagostomy tube feeding is well
tolerated, a study comparing this method to minimal EN
in severely affected animals should be undertaken, with
similar numbers of dogs to be recruited as calculated.
Footnotes
a Sequioa 512, Acuson, Munich, Germany
bMetomide, Delvet Pty Ltd, Seven Hills, NSW, Australia
c Lectade, Jurox Pharmaceuticals, Rutherford NSW, Australia
dAmpiciilin, Aspen Pharmcare Pty Ltd, St Leonard’s, NSW,
Australia
eMetronidazole, Baxter Healthcare, Toongabbie, NSW, Australia
f Stemetil Aventis Pharma, Lane Cove, NSW, Australia
gAlfaxan, Jurox Pharmaceuticals
h Isoflurane, Veterinary Companies of Australia Pty Ltd, King’s
Park, NSW, Australia
iDigestive Low-Fat tinned diet, Royal Canin, Bristol, UK
jCreon, Solvay Pharmaceuticals, Pymble, NSW, Australia
kMCT oil, SHS International Ltd, Liverpool, UK
l cTLI: Commercial radioimmunoassay; Canine TLI Assay, Diag-
nostic Products Corporation, Los Angeles, CA. Testing performed
by the Gastrointestinal Laboratory, Department of Small Animal
Medicine and Surgery, College of Veterinary Medicine, Texas
A&MUniversity, College Station, TX
m spec CPL, Idexx. Enzyme-linked immunosorbent assay; Gastro-
intestinal Laboratory
nCRP measured by solid phase sandwich assay performed by the
Gastrointestinal Laboratory
oGastrin enzyme-labeled immunometric assay performed by Path-
West Laboratory Medicine WA, Royal Perth Hospital, Western
Australia
pCanine serum pancreatic-elastase 1 enzyme immunoassay, per-
formed by ScheBo Biotech AG, Geissen, Germany
q SASv9.1, SAS Institute, Cary, NC
rCefazolin injectable, Mayne Pharma Pty Ltd, Mulgrave, VIC,
Australia
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